 |
7 Diseases |  |
12 Trials |
|
12 Trials |  |
851 News |  |
| «123456789» |
- || Lyumjev (insulin lispro-aabc injection) / Eli Lilly
New P3 trial, Combination therapy: A study to compare an investigational ultra-rapid insulin, LY900014 with another mealtime insulin, Fiasp when both are used along with a long-acting insulin in people with type 1 diabetes (EUDRACT) - Nov 22, 2018
P3, N=632, Terminated, Sponsor: Eli Lilly and Company
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk
Enrollment open: A Research Study Looking at How Faster Aspart Injected in Double Concentration Works in the Body of People With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Oct 31, 2018
P1, N=56, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk
New P1 trial: A Research Study Looking at How Faster Aspart Injected in Double Concentration Works in the Body of People With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Oct 30, 2018
P1, N=56, Not yet recruiting, Sponsor: Novo Nordisk A/S
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk, Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
Enrollment closed, Enrollment change: The Insulin-Only Bionic Pancreas Bridging Study (clinicaltrials.gov) - Oct 22, 2018
P2/3, N=56, Active, not recruiting, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=88 --> 56
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Trial completion date, Trial primary completion date: SNIFF-Quick: Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart (clinicaltrials.gov) - Sep 24, 2018
P1, N=30, Recruiting, Sponsor: Wake Forest University Health Sciences
Recruiting --> Active, not recruiting | N=88 --> 56 Trial completion date: Sep 2018 --> Sep 2019 | Trial primary completion date: Sep 2018 --> Sep 2019
- | Humalog pen (insulin lispro) / Eli Lilly, Lyumjev (insulin lispro-aabc injection) / Eli Lilly
Trial completion: A Meal Test Study of LY900014 in Participants With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Sep 14, 2018
P1, N=80, Completed, Sponsor: Eli Lilly and Company
Trial completion date: Sep 2018 --> Sep 2019 | Trial primary completion date: Sep 2018 --> Sep 2019 Recruiting --> Completed
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk
New P4 trial: Comparison of FiAsp and Aspart During Postprandial Exercise in Adults With Type 1 Diabetes (clinicaltrials.gov) - Sep 5, 2018
P4, N=40, Not yet recruiting, Sponsor: Institut de Recherches Cliniques de Montreal
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
Enrollment open: Evaluation of Fiasp (clinicaltrials.gov) - Aug 24, 2018
P4, N=20, Recruiting, Sponsor: Stanford University
Recruiting --> Completed Not yet recruiting --> Recruiting
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk
Enrollment open, Real-world evidence, Real-world: GoBolus: Study on How Fiasp (clinicaltrials.gov) - Aug 6, 2018
P=N/A, N=686, Enrolling by invitation, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Not yet recruiting --> Enrolling by invitation
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk
Trial completion, Enrollment change: A Trial Comparing the Pharmacokinetic Properties of Fast-acting Insulin Aspart Between Children, Adolescents and Adults With Type 1 Diabetes (clinicaltrials.gov) - Jul 12, 2018
P1, N=46, Completed, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Enrolling by invitation Recruiting --> Completed | N=66 --> 46
- ||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Enrollment closed, Combination therapy: Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes (clinicaltrials.gov) - Jul 9, 2018
P3, N=1072, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Completed | N=66 --> 46 Recruiting --> Active, not recruiting
- ||| Fiasp (fast-acting insulin aspart) / Novo Nordisk
New trial: AP-MFT-01: Comparison of Day and Night Closed-loop With Faster-acting Insulin Aspart With Insulin Aspart (clinicaltrials.gov) - Jul 5, 2018
P=N/A, N=22, Not yet recruiting, Sponsor: Manchester University NHS Foundation Trust
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk, Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
New P2/3 trial: The Insulin-Only Bionic Pancreas Bridging Study (clinicaltrials.gov) - Jun 20, 2018
P2/3, N=88, Recruiting, Sponsor: Massachusetts General Hospital
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk
New P4 trial: Evaluation of Fiasp (clinicaltrials.gov) - Jun 13, 2018
P4, N=20, Not yet recruiting, Sponsor: Stanford University
- ||||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Trial completion, Combination therapy: onset (clinicaltrials.gov) - Apr 5, 2018
P3, N=834, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Humalog pen (insulin lispro) / Eli Lilly, Lyumjev (insulin lispro-aabc injection) / Eli Lilly
Enrollment open, Trial completion date, Trial primary completion date: A Meal Test Study of LY900014 in Participants With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Mar 29, 2018
P1, N=86, Recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Trial completion date: Sep 2018 --> Jun 2018 | Trial primary completion date: Sep 2018 --> Jun 2018
- |||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Trial primary completion date, Combination therapy: onset (clinicaltrials.gov) - Mar 3, 2018
P3, N=803, Active, not recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting | Trial completion date: Sep 2018 --> Jun 2018 | Trial primary completion date: Sep 2018 --> Jun 2018 Trial primary completion date: Feb 2018 --> Feb 2018
- ||| Fiasp (fast-acting insulin aspart) / Novo Nordisk
New trial, Real-world evidence, Real-world: GoBolus: Study on How Fiasp (clinicaltrials.gov) - Mar 1, 2018
P=N/A, N=686, Not yet recruiting, Sponsor: Novo Nordisk A/S
- ||| Humalog pen (insulin lispro) / Eli Lilly, Lyumjev (insulin lispro-aabc injection) / Eli Lilly
New P1 trial: A Meal Test Study of LY900014 in Participants With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Feb 27, 2018
P1, N=86, Not yet recruiting, Sponsor: Eli Lilly and Company
- ||| Fiasp (fast-acting insulin aspart) / Novo Nordisk
New P1 trial: A Trial Comparing the Pharmacokinetic Properties of Fast-acting Insulin Aspart Between Children, Adolescents and Adults With Type 1 Diabetes (clinicaltrials.gov) - Jan 23, 2018
P1, N=66, Recruiting, Sponsor: Novo Nordisk A/S
- ||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Enrollment closed, Combination therapy: onset (clinicaltrials.gov) - Jan 19, 2018
P3, N=803, Active, not recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: Feb 2018 --> Feb 2018 Recruiting --> Active, not recruiting
- ||| Fiasp (fast-acting insulin aspart) / Novo Nordisk
Trial completion: A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Jan 8, 2018
P1, N=61, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Recruiting --> Completed
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Trial completion: A Trial to Evaluate the Pharmacokinetic and Pharmacodynamic Properties of BioChaperone (clinicaltrials.gov) - Dec 12, 2017
P1, N=43, Completed, Sponsor: Adocia
Recruiting --> Completed Recruiting --> Completed
- |||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Trial primary completion date, Combination therapy: onset (clinicaltrials.gov) - Dec 6, 2017
P3, N=1108, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Completed Trial primary completion date: Aug 2017 --> May 2017
- ||| Fiasp (fast-acting insulin aspart) / Novo Nordisk
Trial completion: A Research Study of How Faster-acting Insulin Aspart Moves Into, Through, and Out of the Body and How it Works in the Body When Given Through an Insulin Pump to People With Type 1 Diabetes (clinicaltrials.gov) - Dec 4, 2017
P1, N=58, Completed, Sponsor: Novo Nordisk A/S
Trial primary completion date: Aug 2017 --> May 2017 Active, not recruiting --> Completed
- || Fiasp (fast-acting insulin aspart) / Novo Nordisk
Trial initiation date, Trial primary completion date: A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Nov 6, 2017
P1, N=60, Recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Initiation date: Dec 1956 --> Oct 2016 | Trial primary completion date: Oct 2017 --> Feb 2018
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk
Trial completion: Closed-Loop With Faster Aspart in Young Adults With Type 1 Diabetes (clinicaltrials.gov) - Nov 6, 2017
P=N/A, N=20, Completed, Sponsor: University of Ljubljana, Faculty of Medicine
Initiation date: Dec 1956 --> Oct 2016 | Trial primary completion date: Oct 2017 --> Feb 2018 Active, not recruiting --> Completed
- || Fiasp (fast-acting insulin aspart) / Novo Nordisk
Enrollment closed: A Research Study of How Faster-acting Insulin Aspart Moves Into, Through, and Out of the Body and How it Works in the Body When Given Through an Insulin Pump to People With Type 1 Diabetes (clinicaltrials.gov) - Nov 1, 2017
P1, N=56, Active, not recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk
Enrollment closed: Closed-Loop With Faster Aspart in Young Adults With Type 1 Diabetes (clinicaltrials.gov) - Oct 5, 2017
P=N/A, N=20, Active, not recruiting, Sponsor: University of Ljubljana, Faculty of Medicine
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Enrollment open, Combination therapy: Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes (clinicaltrials.gov) - Sep 21, 2017
P3, N=1072, Recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Trial completion, Combination therapy: onset (clinicaltrials.gov) - Sep 6, 2017
P3, N=1108, Completed, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||||||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
New P3 trial, Combination therapy: Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes (clinicaltrials.gov) - Aug 31, 2017
P3, N=1072, Not yet recruiting, Sponsor: Novo Nordisk A/S
- ||||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Trial completion: Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid (clinicaltrials.gov) - Jul 27, 2017
P3, N=472, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk
Enrollment open: Closed-Loop With Faster Aspart in Young Adults With Type 1 Diabetes (clinicaltrials.gov) - Jul 13, 2017
P=N/A, N=20, Recruiting, Sponsor: University of Ljubljana, Faculty of Medicine
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| Fiasp (fast-acting insulin aspart) / Novo Nordisk
New P1 trial: A Research Study of How Faster-acting Insulin Aspart Moves Into, Through, and Out of the Body and How it Works in the Body When Given Through an Insulin Pump to People With Type 1 Diabetes (clinicaltrials.gov) - Jul 11, 2017
P1, N=56, Recruiting, Sponsor: Novo Nordisk A/S
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk
New trial: Closed-Loop With Faster Aspart in Young Adults With Type 1 Diabetes (clinicaltrials.gov) - Jul 11, 2017
P=N/A, N=20, Not yet recruiting, Sponsor: University of Ljubljana, Faculty of Medicine
- || Fiasp (fast-acting insulin aspart) / Novo Nordisk
Trial initiation date, Trial primary completion date: A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Jul 2, 2017
P1, N=60, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Initiation date: Oct 2016 --> Dec 1956 | Trial primary completion date: Apr 2017 --> Oct 2017
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
New P1 trial: A Trial to Evaluate the Pharmacokinetic and Pharmacodynamic Properties of BioChaperone (clinicaltrials.gov) - Jun 7, 2017
P1, N=42, Recruiting, Sponsor: Adocia
- Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Trial primary completion date: SNIFF-Quick: Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart (clinicaltrials.gov) - Apr 19, 2017
P1, N=30, Recruiting, Sponsor: Wake Forest University Health Sciences
Initiation date: Oct 2016 --> Dec 1956 | Trial primary completion date: Apr 2017 --> Oct 2017 Trial primary completion date: Dec 2016 --> Jul 2018
- ||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Enrollment closed: Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid (clinicaltrials.gov) - Jan 30, 2017
P3, N=450, Active, not recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: Dec 2016 --> Jul 2018 Recruiting --> Active, not recruiting
- ||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Enrollment closed, Combination therapy: onset (clinicaltrials.gov) - Nov 28, 2016
P3, N=1130, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| Fiasp (fast-acting insulin aspart) / Novo Nordisk
Enrollment open: A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Nov 12, 2016
P1, N=60, Recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| Fiasp (fast-acting insulin aspart) / Novo Nordisk
New P1 trial: A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Oct 13, 2016
P1, N=60, Not yet recruiting, Sponsor: Novo Nordisk A/S
- |||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Enrollment open: Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid (clinicaltrials.gov) - Aug 5, 2016
P3, N=450, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Trial primary completion date, Combination therapy: onset (clinicaltrials.gov) - Jul 27, 2016
P3, N=833, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2017 --> Mar 2018
- |||||||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
New P3 trial: Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid (clinicaltrials.gov) - Jul 7, 2016
P3, N=450, Not yet recruiting, Sponsor: Novo Nordisk A/S
- |||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Enrollment open, Combination therapy: onset (clinicaltrials.gov) - May 12, 2016
P3, N=1130, Recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: Dec 2017 --> Mar 2018 Not yet recruiting --> Recruiting
- |||||| Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Enrollment open, Combination therapy: onset (clinicaltrials.gov) - May 5, 2016
P3, N=833, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk
Trial completion: Investigating the Postprandial Glucose Metabolism After Treatment With Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes (clinicaltrials.gov) - May 2, 2016
P1, N=42, Completed, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
Enrollment closed: Investigating the Postprandial Glucose Metabolism After Treatment With Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Apr 6, 2016
P1, N=38, Active, not recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Recruiting --> Active, not recruiting